Introduction
Several studies have demonstrated that patients with temporal lobe epilepsy (TLE) with hippocampal sclerosis (HS) are characterized by a particular clinical phenotype. It is usually difficult to achieve complete seizure control with antiepileptic drugs (AEDs), [1] [2] [3] and cognitive functions, such as memory, are more likely to be impaired than in patients with cryptogenic partial epilepsy. 4 There is also growing evidence in the literature of an association between small hippocampal volumes and depression in subjects with or without epilepsy. 5, 6 In a previous study, 7 we observed that patients with TLE and HS were more likely to develop Seizure (2006) 
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Objective: Hippocampal sclerosis (HS) has been described as a relevant factor for the development of topiramate-related depression and cognitive deficits. The aim of our study was to clarify whether patients with temporal lobe epilepsy (TLE) and HS were also at risk during therapy with levetiracetam (LEV cognitive adverse events (CAEs) and depression during topiramate (TPM) therapy than were patients with cryptogenic TLE, matched for titration schedule of the drug, suggesting a relevant role of HS in TPM-related depression. However, it is not known whether or not these findings are drug-specific.
Levetiracetam (LEV) is one of several new antiepileptic drugs introduced during recent years. It has been shown to be effective as add-on treatment of partial epilepsy, and has a favourable adverse effect profile. 8 Its mechanism of action is not completely clear; recent studies suggest that LEV mode of action is dissimilar to other AEDs. A specific binding site in the central nervous system (CNS), which cannot be displaced by other classic AEDs, has been identified. 9 Recently, it has been showed that the binding site for it is the synaptic vesicle protein SV2A, with a neuromodulating effect on neurotransmission. 10 We previously described aggressiveness and emotional lability as the main treatment-emergent adverse events during therapy with LEV in patients with epilepsy.
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The aim of this study was to evaluate whether patients with HS were more prone to develop CAEs and depression with LEV, as we had earlier shown with TPM. 7 
Methods
Data was collected from a population of consecutive patients with epilepsy started on LEV at the National Hospital for Neurology and Neurosurgery (Queen Square) and the Chalfont Centre for epilepsy, between November 2000 and November 2002, to assess psychiatric treatment emergent adverse events of LEV. 11 The study was conducted using the same methods previously described 7 that we briefly summarize here. All subjects had high-resolution, thin section magnetic resonance imaging (MRI) scans as part of the routine assessment. The diagnosis of HS was made visually by specialist neuroradiologists considering as diagnostic criteria the presence of hippocampal atrophy demonstrated with T1-weighted coronal inversion-recovery images and increased signal intensity within the hippocampus in T2-weighted images. 12 These represent widely used and reproduced criteria for neuroimaging in patients with epilepsy. 13 Demographic and clinical details were extracted from case records and the classification of the epilepsy type was defined on the basis of clinical symptoms (complex partial seizures), EEG and MRI findings compatible with TLE. 14 We identified two groups: those with evidence of unilateral or bilateral HS (HS group) and those with normal MRI (MRI negative group). Patients with lesional TLE (tumor, vascular malformation, neuronal migration disorders or scar), and those with both foreign tissue lesions and HS were excluded. We compared the HS group with a normal MRI group of patients, matched for age, sex, starting dose and titration schedule of LEV.
PAEs were assessed by evaluating patients at each visit and were defined as psychiatric manifestations that occurred during LEV therapy and were not related to other AEDs changes, physical illness or personal events, in patients without a psychiatric disorder when LEV was started. Psychopathology was evaluated with clinical interview assessing the patient at each visit, according to patient's need, and was classified according to DSM-IV criteria, while some other behavioural changes have been classified as anger/hostile behaviour, aggressive behaviour, agitated behaviour, irritability or anxiety. The concept of PAEs has been described in detail in other papers from our group. 7, 11, 15, 16 CAEs were identified by spontaneous patient reports and clinical evaluation; adverse effects that were present before LEV was started were not included.
The following items were assessed: age, gender, age at onset of epilepsy, personal history of febrile convulsions, EEG laterality, seizure frequency before LEV therapy, antiepileptic drugs prescribed, seizure freedom attained or at least 50% seizure reduction with LEV, presence of cognitive adverse events (CAEs), severity of CAEs (classified as mild, moderate or severe), and the presence of psychiatric adverse events (PAEs).
Chi-squared analysis or Fisher's exact test were used for categorical data, while ordinal and linear data were assessed using nonparametric tests and one-way analysis of variance. Differences and correlations were considered statistically significant at p < 0.05. Correction for multiple comparison tests was used when appropriate.
Results
Seventy-eight patients with TLE and HS were identified (male/female ratio 36/42), mean age (S.D.) 38.1 (10.4) years. There were 42 patients with leftsided HS, 32 with right-sided and 4 with bilateral HS. The MRI-negative group consisted of 78 patients matched for age, gender, starting dose and titration schedule of LEV (Table 1) .
In the HS group 44 patients had a starting dose of 500 mg and a titration schedule of 500 mg every week; 34 patients started with 1000 mg and had a titration dose of 1000 mg every week. We matched one patient with a normal MRI for each patient in the HS group.
Significant differences between the two groups are shown in Table 1 . Patients with HS were characterized by an earlier age of epilepsy onset (7.7 years, S.D. 6.8) than controls (11.2 years, S.D. 9.5, p = 0.009). In the HS group, 55% had a previous history of febrile convulsions compared with only 20% in the control group ( p < 0.001).
The LEV dose range was 500-4000 mg with a mean dose (AES.D.) of 2300 (AE1000) mg in both groups.
No differences in prevalence of CAEs between patients with HS and matched controls were observed. There were no differences in 50% seizure reduction or seizure freedom attained (10% of patients with HS became completely seizure free and 44% reached at least 50% seizure reduction).
As far as psychopathology is concerned, we did not find significant differences in the occurrence of psychosis, anxiety, depression or aggressive behaviour.
Discussion
Mesial TLE (MTLE) is a common form of human epilepsy and HS is often the related pathology. 1 Our results confirm the previous literature concerning the characteristics of TLE and HS. 3 A previous history of febrile convulsions, onset of habitual seizures during, or shortly after, the first decade of life, and longer duration of epilepsy are significantly associated with MTLE when HS is also present. We previously observed that these patients were more vulnerable to developing a specific spectrum of adverse effects characterized by depression and cognitive complaints during TPM therapy than were patients without HS, despite the same titration schedule of the drug. 7 In this study, we failed to demonstrate the same association with LEV therapy. The lack of a formal psychometric testing for the assessment of depression is a limitation of our study. However, we have used a clinical interview to identify emergent psychopathology and the necessary information was documented to allow a satisfactory evaluation of the relationship between hippocampal sclerosis and affective state in patients treated with LEV. Moreover, our aim was to replicate the previous study on TPM, so we used the same methodology. In this light, our findings might suggest that patients with HS are more likely to develop cognitive impairment and depression mainly when taking AEDs with prominent GABAergic properties such as TPM, or, on the other hand, that LEV may have a positive impact on cognition and mood, reducing the biological vulnerability of patients with TLE and HS. The low prevalence of depression in our groups is striking. In our previous study on TPM, 7 the prevalence of depression in patients with TLE, either with or without HS, was 25 and 12.5% respectively. In this study, we observed a 2.5 and 5% in the two groups. These findings are in line with the reported spectrum of PAEs of the two AEDs that is mainly characterized by mood disorder with TPM 15 rather than with LEV, 11 but also suggest that the role of the drug is relevant with regard to the occurrence of psychopathology even in predisposed patients. TPM and LEV are quite different with respect to their mechanisms of action. TPM modulates GABAergic neurotransmission, inhibits a carbonic anhydrase subtype enzyme, attenuates L-type calcium channel currents, inhibits voltage sensitive sodium channels and blocks kainate or a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA/kainate) subtype of glutamate receptors. 17 Several studies have suggested that GABA-ergic potentiation might be a prominent mode of action for TPM, especially if
The role of hippocampal sclerosis in antiepileptic drug-related depression patients the drug is rapidly titrated. [18] [19] [20] In general, GABAergic AEDs have been shown to affect cognitive functions and to be associated with depressive symptoms more frequently than AEDs with other mechanisms of action. 21 Among first generation drugs, phenobarbital is the only one with a specific adverse effect profile related to memory functions and mood. 22 Subsequently, other AEDs such as vigabatrin 23 and tiagabine 24 have been associated with a similar profile, especially on mood. All this evidence, taken together with our findings on patients with TPM, might suggest that patients with TLE and HS are indeed more at risk of developing this specific spectrum of adverse effects than those without HS, an effect mainly seen with the prescription of GABA-ergic drugs. The presence of hippocampal atrophy and GABA-ergic hyperactivity might play a basic role in the neurobiology of depressive symptoms in epilepsy.
On the other hand, our findings might also suggest a positive psychotropic profile of LEV. In controlled clinical trials, the prevalence of CAEs such as confusion, abnormal thinking or memory impairment was 1-1.6%, 25 and preliminary studies reported an improvement in memory functions and a nootropic effect of LEV in both adults and children with epilepsy. [26] [27] [28] We found no differences in seizure control with LEV therapy between the two groups, suggesting that the cognitive complaints of the patients are not related to a difference in seizure control.
These findings may have theoretical value with respect to the role of HS in depression and cognitive problems during AED therapy. Further studies, replicating our findings and investigating different AEDs in this subgroup of patients, would be of interest.
